IRVINE, Calif., July 22, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the 2025 class of entrepreneurs who will participate in The Confidence Project: Empowering Women Entrepreneurs. This initiative, led by BOTOX® Cosmetic, is aimed at closing the Confidence Gap and accelerating business growth for select entrepreneurs from across the country. Meet the Entrepreneurs: Introducing The Confidence Project's 2025 Class BOTOX® Cosmetic (onabotulinumtoxinA) Selects This ...

Summary of Key Points from the Conference Call Industry Overview - **Industry**: Biopharma in North America - **Market Analysis**: Comprehensive analysis of the US drug market conducted by IQVIA Rx Key Market Metrics - **Total Prescription Year-over-Year (YoY) Growth**: - Latest weekly growth (week ending July 11, 2025) was +4.0%, up from +3.4% the previous week and +2.5% over the past 12 weeks [1][6] - For the week ended July 11, the total market weekly TRx YoY change was +4.0%, compared to +1.8% a year ago [2] Prescription Trends - **Rolling 4-week TRx YoY**: +3.0% - **Rolling 12-week TRx YoY**: +2.5% - **Extended Unit (EUTRx) Weekly YoY Growth**: +3.3%, which is below the TRx YoY [2] - **Sequential Weekly TRx Growth**: +12.0%, a significant increase compared to -7.3% the week before [2] Company-Specific Insights - **Bristol Myers Squibb (BMY)**: - Cobenfy approved for schizophrenia on September 26, 2024, with scripts at ~2,040 for the week, up from ~1,820 the previous week [3] - To meet 2025 consensus expectations, Cobenfy TRx needs to track at ~2-3x the volumes from recent schizophrenia launches [3] - **Vertex Pharmaceuticals (VRTX)**: - Journavx approved for acute pain on January 30, 2025, with scripts at ~5,880 for the week, up from ~5,180 the previous week [4] - Hospital scripts, which are not captured by IQVIA, account for ~28% of total scripts [4] - **Gilead Sciences (GILD)**: - Yeztugo approved on June 18, 2025, with latest week TRx at ~70, up from ~20 the previous week [5] - Yeztugo's injectable formulation accounted for 54% of total TRx [5] Competitive Landscape - **Launch Comparisons**: - GILD's Yeztugo compared to Descovy and Apretude [5] - BMY's Sotyktu launch tracked against AMGN's Otezla [9] - LLY's Kisunla launched in July 2024 for Alzheimer's [9] Pricing and Sales Analysis - **Immunology Pricing**: Updated charts for 2Q25 for Stelara and Tremfya, analyzing how additional indications impact price per script [10] - **Biosimilar Adoption**: Comprehensive analysis of biosimilars across various branded drugs [12] Notable Trends - **Seasonal Respiratory Vaccine Tracking**: Exhibits tracking RSV and COVID vaccine weekly and monthly TRx launch trends [11] - **Key Products Performance**: Detailed tracking of TRx market share and performance for major pharmaceutical companies [48] Conclusion - The biopharma industry in North America is experiencing positive growth in total prescriptions, with significant contributions from new product launches and competitive dynamics among major players. The analysis indicates a robust market environment with potential investment opportunities in emerging therapies and established products.

Group 1 - AbbVie received a "buy" rating from Morgan Stanley analyst Terrence Flynn, with a target price of $250 [1] - For Q1 FY2025, AbbVie reported adjusted diluted EPS of $2.46, a year-over-year increase of 6.5%, and net revenue of $13.343 billion, reflecting an 8.4% growth rate [1] - The company is expected to announce Q2 FY2025 earnings on July 31, 2025, with projected revenue of $14.9667 billion and EPS of $1.527 [1] Group 2 - AbbVie's immunology segment showed strong performance, with sales of Skyrizi and Rinvoq reaching $3.43 billion and $1.72 billion, respectively, representing year-over-year increases of approximately 70% and 57% [1] - The company is focusing on early business development opportunities in oncology and neuroscience to drive growth over the next eight years [1] Group 3 - AbbVie made significant progress in its R&D pipeline, showcasing early-stage developments at the 2025 AACR annual meeting, including new ADC ABBV-969 and CCR8-targeting antibody ABBV-514 [2] - CEO Robert Michael stated that AbbVie plans to invest $10 billion in U.S. manufacturing over the next decade to mitigate impacts from U.S. tariff policies and drug pricing proposals [2] - AbbVie remains competitive among the top ten global pharmaceutical companies, facing competition from Johnson & Johnson, Novartis, and Merck, but is expected to maintain its leading position due to its innovation in immunotherapy and ongoing investment in new drug development [2]

Group 1 - The primary goal of the "High Income DIY Portfolios" Marketplace service is to provide high income with low risk and capital preservation for DIY investors [1] - The service offers seven portfolios designed for income investors, including retirees or near-retirees, featuring three buy-and-hold portfolios, three rotational portfolios, and a conservative NPP strategy portfolio [1] - The portfolios include two high-income portfolios, two dividend growth investment (DGI) portfolios, and a conservative NPP strategy portfolio aimed at low drawdowns and high growth [1] Group 2 - The stocks highlighted in the article are candidates for further research rather than direct buy recommendations, emphasizing the need for due diligence based on personal goals and risk tolerance [2] - The author has disclosed beneficial long positions in a wide range of companies, indicating a vested interest in the stocks mentioned [2]

Core Viewpoint - The U.S. markets have experienced volatility, but dividend-paying stocks can provide substantial passive income even during market fluctuations [1] Group 1: Verizon Communications - Verizon offers a sustainable 6.5% dividend yield, translating to $2.71 annually per share, and has raised its dividend for 18 consecutive years [5][6] - The company reported its highest-ever quarterly adjusted EBITDA of $12.6 billion in Q1 2025, with free cash flow of $3.6 billion and a dividend payout ratio of 64.2%, indicating strong earnings to cover dividends [6] - Verizon's convergence strategy has reduced customer churn by 40% to 50%, leading to predictable cash flows [7] - In Q1, Verizon added 339,000 broadband customers and 308,000 fixed wireless customers, aiming for 100 million premises with fiber and fixed wireless access [8] - The adjacent services business is expected to reach a $2 billion annual run rate by the end of 2025, with management guiding for 2% to 3.5% adjusted EBITDA growth [9] - Verizon is positioned as a smart buy for investors seeking passive income from high-quality companies [10] Group 2: AT&T - AT&T offers a solid 4.1% yield, translating to $1.11 per share annually, with a 68.1% dividend payout ratio, allowing for potential dividend increases [11] - The company reduced its net debt by $32 billion since 2020, ending Q1 2025 with a net debt-to-adjusted EBITDA ratio of 2.63 [12] - AT&T's revenues increased by 2% to $30.6 billion in Q1, with net income rising 23.6% year over year to $4.7 billion [12] - The company operates the largest fiber network in the U.S., expecting to reach 30 million fiber locations by mid-2025 and 50 million by 2029, driving strong customer growth [13] - Bundling services has created stickier customer relationships, making AT&T an appealing pick for income investors seeking defensive dividend growth [14] Group 3: AbbVie - AbbVie offers a 3.52% yield with an annual payout of $6.56 per share and has a history of increasing dividends for 53 consecutive years [15] - Despite losing patent protection for Humira, AbbVie has diversified its portfolio and reduced reliance on the drug, with next-generation drugs generating $5.1 billion, a 65% year-over-year increase [17] - The company is focusing on strategic investments, including a $350 million obesity partnership and a $2.1 billion acquisition of Capstan Therapeutics, positioning itself in high-growth areas [18] - Recent IPR&D and milestone expenses have negatively impacted second-quarter earnings guidance, but these deals may drive long-term growth [19]

Core Viewpoint - Dividend growth stocks may not be the most exciting investments but are designed to build growing income for investors [1] Group 1: Investment Strategy - The focus is on high-quality and reliable dividend growth ideas that provide stability and long-term wealth creation [1] - The service also includes ideas for writing options to further enhance investors' income [1] Group 2: Membership Benefits - Membership provides access to a portfolio, watchlist, and live chat [2] - Members receive first access to all publications and exclusive articles not available elsewhere [2]

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

Company Performance - AbbVie (ABBV) closed at $190.58, marking a +2.25% move from the prior day, outperforming the S&P 500's gain of 0.32% [1] - Over the past month, AbbVie shares appreciated by 0.49%, while the Medical sector experienced a loss of 3.4% [1] Upcoming Earnings - AbbVie is expected to release its earnings report on July 31, 2025, with analysts forecasting earnings of $3.02 per share, indicating a year-over-year growth of 13.96% [2] - The consensus estimate anticipates revenue of $15.04 billion, reflecting a 3.97% increase from the same quarter last year [2] Annual Estimates - For the annual period, Zacks Consensus Estimates project earnings of $12.07 per share and revenue of $60.12 billion, representing shifts of +19.27% and +6.72% respectively from the previous year [3] - Recent changes in analyst estimates suggest a favorable outlook on AbbVie's business health and profitability [3] Valuation Metrics - AbbVie is currently trading at a Forward P/E ratio of 15.44, which is a premium compared to the industry average of 14.02 [6] - The company has a PEG ratio of 1.23, aligning with the average PEG ratio of the Large Cap Pharmaceuticals industry [7] Industry Ranking - The Large Cap Pharmaceuticals industry, part of the Medical sector, holds a Zacks Industry Rank of 62, placing it in the top 26% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Core Insights - AbbVie has been expanding its oncology portfolio, now including five therapies for various cancers, contributing over 12% to its first-quarter revenues, which grew 6% year over year [1][2] AbbVie's Oncology Segment - The estimated sales for AbbVie's oncology segment in Q2 2025 are projected to be $1.6 billion, reflecting a 2% year-over-year decline, primarily due to the decline in Imbruvica sales amid rising competition [2][7] - Despite the decline, Venclexta, Epkinly, and Elahere are expected to contribute to growth, while modest revenues from Emrelis are anticipated following its approval in mid-May [2][7] Competitive Landscape - Major competitors in the oncology space include AstraZeneca, Merck, and Pfizer, with AstraZeneca's oncology sales accounting for nearly 41% of total revenues and growing 13% in Q1 2025 [4] - Merck's Keytruda accounted for over 46% of its total revenues in Q1 2025, while Pfizer's oncology revenues grew 7% on an operational basis, now accounting for over 27% of its total revenues [5] Valuation and Performance - AbbVie shares have outperformed the industry year to date, trading at a price/earnings (P/E) ratio of 14.21, slightly below the industry average of 15.16 [6][8] - EPS estimates for 2025 have decreased from $12.28 to $12.08, while estimates for 2026 have increased from $14.05 to $14.06 over the past 30 days [10]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [3] Core Insights - AbbVie has made a strategic investment of $1.925 billion in the CD3/BCMA/CD38 trispecific antibody ISB 2001 from IGI Therapeutics, acquiring exclusive rights in North America, Europe, Japan, and Greater China. This follows a previous investment of $1.055 billion in 2024 for another trispecific antibody, indicating a strong focus on the hematological oncology sector and highlighting investment opportunities in TCE multispecific antibodies [5][14][17] - The pharmaceutical and biotechnology sector has shown a weekly return of 2.82%, outperforming the CSI 300 index by 1.56%, ranking 6th among 31 primary sub-industry indices. The medical services sub-sector had the highest weekly increase of 7.73%, while the pharmaceutical commerce sub-sector had the lowest at 1.12% [4][14] - The innovative drug industry is experiencing a surge in large-scale business development (BD) transactions, indicating a recovery in investment and financing within the biopharmaceutical sector. This trend is expected to boost R&D investments and accelerate project progress, particularly benefiting CXO and upstream life sciences industries [5][14] Summary by Sections 1. Industry Weekly Viewpoints - The pharmaceutical and biotechnology sector's performance has been strong, with significant investments in innovative therapies, particularly in the TCE multispecific antibody space [14] - Recent regulatory updates include the prohibition of a specific surgical technique for Alzheimer's treatment due to insufficient evidence, and the reclassification of a drug from prescription to over-the-counter [14] 2. Market Performance and Valuation - The pharmaceutical and biotechnology industry has underperformed the CSI 300 index by 0.95 percentage points over the past month, with a 1-month increase of 2.20%. However, it has outperformed the index over the past three and six months [25][28] - The current price-to-earnings (P/E) ratio for the industry is 28.97, which is below the historical average of 30.10 [28]